Table 2.
Strategies for treatment individualization in elderly patients
* For fit patients: Bz subcutaneous (SQ) and biweekly for first cycle and weekly thereafter; thalidomide: up to 200 mg; lenalidomide: full doses; melphalan: 9 mg/m2; dexamethasone: 40 mg weekly.
† For unfit patients: Bz SQ and weekly; thalidomide: 100 mg; melphalan: 7 mg/m2; dexamethasone: 20 mg weekly.
‡ For frail patients: thalidomide: up to 50 mg; lenalidomide: 10–15 mg; cyclophosphamide instead of melphalan: 50 mg daily; bortezomib SQ: 1 mg/m2 weekly; prednisone instead of dexamethasone: 30 mg on alternate days.
